Compare FRSX & SXTP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRSX | SXTP |
|---|---|---|
| Founded | N/A | 2010 |
| Country | Israel | United States |
| Employees | N/A | 3 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9M | 4.4M |
| IPO Year | 2016 | N/A |
| Metric | FRSX | SXTP |
|---|---|---|
| Price | $1.87 | $1.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.10 |
| AVG Volume (30 Days) | ★ 1.6M | 74.7K |
| Earning Date | 05-15-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $33.92 |
| Revenue Next Year | N/A | $51.35 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.31 | $0.34 |
| 52 Week High | $3.00 | $8.62 |
| Indicator | FRSX | SXTP |
|---|---|---|
| Relative Strength Index (RSI) | 53.61 | 62.15 |
| Support Level | $1.24 | $1.29 |
| Resistance Level | $1.90 | $1.82 |
| Average True Range (ATR) | 0.16 | 0.15 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 73.33 | 70.18 |
Foresight Autonomous Holdings Ltd is a technology company engaged in the development of 3D perception systems and cellular-based applications. The company designs, develops, and commercializes in-line-of-sight vision systems and beyond-line-of-sight accident prevention solutions through its subsidiaries. Its solutions are based on stereo vision, 3D perception, and V2X technologies, aimed at improving safety by enabling accurate obstacle detection and real-time alerts. The company targets multiple industries, including automotive, defense, agriculture, and heavy equipment.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.